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Fetal growth restriction is an important pregnancy complication that has major consequences for the fetus and neonate as well as
an increased risk of long-term morbidity extending into adulthood. The precise aetiology of most cases of fetal growth restriction
is unknown although placental thrombosis is a common feature in many of these cases. This paper will outline the potential role
of proteoglycans in contributing to placental thrombosis and fetal growth restriction.
1.Introduction
Adverse pregnancy outcomes remain a major cause of
perinatal and paediatric morbidity and mortality, and sub-
sequent morbidity into adult life. One of the key causes
o fa d v e r s ep r e g n a n c yo u t c o m ei sf e t a lg r o w t hr e s t r i c t i o n
(FGR).Fetalgrowthrestrictiondescribesasituationinwhich
the fetus fails to achieve its full growth potential in utero.
While an aetiology can be ascribed in a number of cases,
the precise aetiology remains uncertain in up to 70% of
cases. The ability to predict “at risk” pregnancies is limited,
and therapeutic strategies are largely restricted to ultrasound
surveillance for evidence of fetal decompensation secondary
to hypoxia and then timely intervention by delivery. There
is a trade oﬀ between delivering too early with the resultant
risks of prematurity and delaying delivery with the attendant
risks associated with hypoxia, neurological damage, and fetal
demise. Of further concern is the accumulating evidence
that growth-restricted fetuses are at increased risk of long-
term postnatal sequelae including obesity, type II diabetes,
hypertension, cardiovascular disease, and premature death
[1]. While a number of maternal and fetal factors have been
identiﬁedwhichcontributetoFGR,theaetiologiesofthevast
majority of cases remain uncertain [2]. The pathogenesis of
FGR appears to be related to abnormalities in the placental
vascular ﬂow [3] possibly due to microvascular thrombosis
within the placenta [4]. The importance of understanding
the mechanisms that control coagulation within the placenta
cannot be overemphasised. Dysregulation of coagulation
within the placenta is one of the few mechanisms which may
potentially be amenable to therapy via anticoagulant treat-
ment (including the development of speciﬁc targeted antico-
agulants),henceitisimperativethatthishithertounexplored
area of placental function be rigorously investigated.
2. Regulation of Thrombin within the Placenta
Normal human pregnancy is characterised by increased
thrombin generation resulting in a shift towards a hyper-
coaguable state [5]. Amongst factors responsible for this
alteration in systemic haemostasis is the possibility that
excessive thrombin production may originate in the placenta
[6].Despitethis,theplacentaeofnormalhumanpregnancies
are not characterized by excessive intravascular thrombosis,
suggesting that factors within the placenta itself may oﬀset
the trend toward hypercoaguability within this organ [6].
In contrast, excessive uteroplacental thrombosis has been
proposed as the pathogenic mechanism leading to a range of
pregnancy complications including fetal growth restriction
[4, 7, 8]. Histopathologic assessment of placentae from a
range of pregnancy complications has demonstrated the
presence of mural thrombi within both the maternal and
fetal compartments of the placenta [9–12].2 Journal of Pregnancy
It is likely that the coagulation disturbance seen with
FGR arises within the placenta itself rather than within
the systemic circulation of either the fetus or the mother.
Despite early work suggesting associations between inherited
thrombophilias and adverse pregnancy outcomes [13, 14],
numerous case-control studies [15, 16]a n dp r o s p e c t i v e
cohort studies [17–19] examining maternal thrombophilias
have failed to conﬁrm signiﬁcant associations between
FGR and thrombophilias. Furthermore, recent prospective
cohort studies have suggested that most patients with
thrombophilias do not develop pregnancy complications and
that most patients who do develop these complications
do not carry a thrombophilic marker [17–19]. Likewise,
several studies investigating the possible contribution of fetal
or neonatal inherited thrombophilias to adverse pregnancy
outcomes have failed to conﬁrm this association [15, 16].
While it remains possible that the placental thrombosis
that is observed in patients with these adverse pregnancy
outcomes may be due to other (as yet unidentiﬁed)
thrombophilic markers, a more likely explanation is that
the coagulation disturbance arises within the placenta
itself.
3.Proteoglycans
Proteoglycansaremacromoleculeslocatedwithinvesselwalls
that contain a core protein to which sulphated glycosamino-
glycan (GAG) chains are covalently linked. There are four
types of GAG chains located in the blood vessel wall:
chondroitin sulphate, dermatan sulphate, heparan sulphate,
and hyaluronan [20]. However, only chondroitin sulphate,
dermatan sulphate, and heparin sulphate are covalently
linked to a core protein [20].
Placentae contain two major types of proteoglycans;
those containing heparan sulphate and those containing
chondroitin sulphate or dermatan sulphate [21]. Heparan
sulphate proteoglycans in the placenta include syndecan
a n dp e r l e c a n[ 22, 23] while chondroitin sulphate and
dermatan sulphate containing proteoglycans in the placenta
include decorin and biglycan [24]. Decorin usually has one
chondroitin sulphate or dermatan sulphate GAG attached to
its core protein, while biglycan normally has two of these
GAGs attached to its core.
Swan et al. have previously demonstrated that decorin
is localised to the stroma surrounding fetal blood vessels of
placental villi [25], whereas Murthi et al. demonstrated that
biglycan is localized to endothelial and smooth muscle cells
of fetal capillaries [26]. In contrast, syndecan 1 was highly
expressed in the syncytiotrophoblast [27].
4.Actions ofProteoglycansandGAGsin
the HumanPlacenta
Proteoglycans and their GAG sidechains have been shown
to have important actions within the placenta. These
molecules display important anticoagulant actions which
suggest they may play a key role in preventing thrombotic
events within the placenta [6, 28]. Heparan sulphate chains
bind Antithrombin through a pentasaccharide sequence,
while dermatan sulphate chains bind heparin cofactor II
(HCII) through a highly charged sequence [28]G A Gb o u n d
antithrombin and HCII are thought to undergo a confor-
mational change, which in turn facilitates the inhibition
of thrombin [29, 30]. The cellular localization of PGs to
endothelium and cells in contact with circulating blood,
suggest an important role for these molecules in localized
anticoagulation.
5. Could Proteoglycans Contribute to FGR?
Swan et al. demonstrated a signiﬁcant reduction in the
mRNA and protein expression of decorin in placentae
from human pregnancies complicated by FGR compared
to gestation matched controls [25]. Likewise, Murthi et al.
demonstrated a signiﬁcant reduction in the mRNA and
protein expression of biglycan in FGR compared to gestation
matched controls. Both studies conﬁrmed the localization of
these molecules in close proximity to circulating blood, sup-
porting the hypothesis that localized anticoagulant activity
may be reduced in FGR placentae. Whether these changes
correlate with the increased placental thrombosis observed
in FGR placentae remains uncertain. Likewise, it is plausible
that the pathophysiological process resulting in FGR is
not purely restricted to alterations in thrombin regulation,
since decorin has been shown to interact with insulin-like
growth factor-1 [31], thereby raising the possibility that
altered decorin expression may interfere with growth factor
expression and hence fetal growth. Decorin has also been
shown to inhibit trophoblast proliferation and migration
[32, 33] raising yet another potential mechanism by which
altereddecorinexpressionmayplayaroleinthepathogenesis
o ff e t a lg r o w t hr e s t r i c t i o n .
Fetal growth restriction is commonly associated with
pre-eclampsia and hypertensive disorders of pregnancy [2].
Altered GAG sulphation patterns have been observed in
placentae from pregnancies complicated by pre-eclampsia
[34], raising the possibility that this could result in altered
GAG function and thereby contribute to the development
of pre-eclampsia. Chen et al. have also demonstrated upreg-
ulation of proteoglycan expression and alterations in the
GAG composition in placentae from women with gestational
diabetes and hyperglycaemia [24]. Gestational diabetes is
typicallyassociatedwithfetalovergrowth;however,increased
fetal morbidity and mortality are well recognized [35]. It
is plausible that altered placental proteoglycan homeostasis
may be an important mechanism contributing to the poorer
perinatal outcomes observed in all these pregnancy compli-
cations.
However, determining causation is not always easy in
human pregnancy research so it remains uncertain whether
the alterations in proteoglycan expression observed are truly
causative, or rather reﬂect a response to an altered growth
process. Ishiguro et al. has demonstrated alterations in
placental vasculature in Syndecan 4 knockout mice with
greater evidence of ﬁbrin and calcium deposition suggesting
disruptionofthelocalanticoagulantmechanisms,althougha
statistically signiﬁcant growth disturbance was not seen [36].Journal of Pregnancy 3
6. PotentialTherapies
At present, there are no proven treatments for FGR. Under-
standing the potential role of proteoglycans in contributing
to FGR is important as it may allow the rational use of
therapeutic glycosaminoglycans (i.e., heparins) to augment
the anticoagulant activities of proteoglycans. The challenge,
however, is to ensure that this anticoagulant activity is
delivered to the compartment of the placenta in which the
functional defect can be demonstrated and that undesired
eﬀects of systemic anticoagulation for either mother or fetus
can be avoided.
7. Conclusion
Fetal growth restriction is a serious pregnancy complica-
tion that cannot currently be “treated” during pregnancy.
Management relies on appropriate detection and timely
intervention by delivery to prevent the serious consequences
of this condition. This often necessitates the delivery of
extremely premature infants who require the investment of
a considerable range of ﬁnancial, intellectual, and emotional
resources to ensure their survival. Furthermore, these infants
are at risk of developing the long-term consequences of these
conditions which may not become apparent until adulthood
such as an increased risk of obesity, cardiovascular disease,
and diabetes. Understanding the pathophysiological role of
proteoglycans in the placenta may provide an important
therapeutic window to prevent or treat fetal growth restric-
tion in the future. There is no doubt that eﬀorts to improve
the fetal and neonatal outcomes for these infants appear well
justiﬁed given the possible life-long improvements which
may ensue.
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